STC’s new appointments in line with Vision 2030

Updated 14 January 2019

STC’s new appointments in line with Vision 2030

The Saudi Telecom Company (STC) has announced new appointments of a number of senior Saudi executives. These include the appointments of Haithem bin Mohammed Al-Faraj as senior vice president — technology and operations; Alayan bin Mohammed Al-Wateed as senior vice president — customer unit; Badr bin Abdullah Al-Lahib as vice president — operation sector in the technology and operations unit; Abdullah bin Mohsen Al-Owaini as vice president — applications sector in the technology and operations unit; and Riyad bin Hamdan Al-Enzi as vice president — customer care sector in the customer unit.
STC CEO Nasser bin Suleiman Al-Nasser said that STC is committed to empowering Saudi cadres based on their qualifications and expertise and to appointing qualified young Saudis in leadership positions, in order to enhance the performance of the STC Group. This, he said, is in line with STC’s “pivotal role in enabling the digital transformation of the Kingdom’s public and private sectors in accordance with Vision 2030.”
Al-Nasser added: “This also comes in line with STC’s ‘Dare’ strategy to lead the transformation and development in new paths, especially with the rapid changes in the global ICT sector.”
STC is a leading telecommunications company in Saudi Arabia that offers landline, mobile, internet services and computer networks.


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.